// App-Quantinova.ai

: A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

Researchers

Presenter

  • William B. Donnellan

Principal Investigators

  • Ehab L. Atallah

  • Adam S. Asch

  • Manish R Patel

  • Julie Charlton

  • Alexander MacDonald

  • Elena Young

  • Elizabeth Sainsbury

  • Donald Strickland

  • Suzanne Jones

  • Philip Overend

  • Carrie A. Adelman

  • Jon Travers

  • Simon Smith

  • J. Elizabeth Pease

  • Wolfram Brugger

Medical Centers

  • Tennessee Oncology, Nashville, TN

  • Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

  • Stephenson Cancer Center/The University of Oklahoma Health Sciences Center, Oklahoma City, OK.

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Oncology IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom

  • Quantitative Clinical Pharmacology, ECD, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom

  • Sarah Cannon Development Innovations, Nashville, TN

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • AZD-1152

  • AZD-2811

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Adaptive

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved